{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:46:32Z","timestamp":1789757192484,"version":"4.0.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1093\/jac\/dkm521","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T01:54:05Z","timestamp":1201830845000},"page":"734-742","source":"Crossref","is-referenced-by-count":46,"title":["Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients"],"prefix":"10.1093","volume":"61","author":[{"given":"Katherine","family":"Allinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig","family":"Kolve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans G.","family":"Gumbinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Josef","family":"Vormoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Ehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"key\n\t\t\t\t20170511114108_DKM521C1","first-page":"179","article-title":"Special aspects related to invasive fungal infections in children with cancer","volume-title":"Bailleres Clinical Infectious Diseases","author":"Ritter","year":"1995"},{"key":"key\n\t\t\t\t20170511114108_DKM521C2","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/313445","article-title":"Aspergillosis in children with cancer: a 34-year experience","volume":"29","author":"Abbasi","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1439-0507.1999.00496.x","article-title":"Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival","volume":"42","author":"Groll","year":"1999","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20170511114108_DKM521C4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00043426-200304000-00004","article-title":"Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases","volume":"25","author":"Wright","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.inf.0000220256.69385.2e","article-title":"Fungal infections in children with cancer: a prospective, multicenter surveillance study","volume":"25","author":"Castagnola","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20170511114108_DKM521C6","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-1161","article-title":"Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000","volume":"117","author":"Zaoutis","year":"2006","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20170511114108_DKM521C7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1086\/503844","article-title":"Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies","volume":"42","author":"Sipsas","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/520274","article-title":"Impact of previous aspergillosis on the outcome of bone marrow transplantation","volume":"26","author":"Offner","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbmt.2004.02.006","article-title":"Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center","volume":"10","author":"Fukuda","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20170511114108_DKM521C10","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood-2006-03-008706","article-title":"Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511114108_DKM521C11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1096-911X(199704)28:4<268::AID-MPO5>3.0.CO;2-G","article-title":"Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia","volume":"28","author":"Hoover","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C12","first-page":"297","article-title":"Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature","volume":"82","author":"Martino","year":"1997","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170511114108_DKM521C13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.1187","article-title":"Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion","volume":"68","author":"Nosari","year":"2001","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.10447","article-title":"Stem cell transplantation post invasive fungal infection is a feasible task","volume":"75","author":"Avivi","year":"2004","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704469","article-title":"Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients","volume":"33","author":"Cordonnier","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170511114108_DKM521C16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000083447","article-title":"Hematopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B","volume":"113","author":"Kruger","year":"2005","journal-title":"Acta Haematol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C17","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","article-title":"Clinical pharmacology of antifungal compounds","volume":"17","author":"Groll","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20170511114108_DKM521C19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511114108_DKM521C22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bmt.1703763","article-title":"Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation","volume":"30","author":"Mattei","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170511114108_DKM521C23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20170511114108_DKM521C24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00520-003-0523-z","article-title":"Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience","volume":"11","author":"Cesaro","year":"2003","journal-title":"Support Care Cancer"},{"key":"key\n\t\t\t\t20170511114108_DKM521C25","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511114108_DKM521C26","first-page":"p. 406","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children","author":"Walsh"},{"key":"key\n\t\t\t\t20170511114108_DKM521C27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C28","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: a randomized, prospective trial of a high loading regimen versus a standard dosing (AmBiLOAD Trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170511114108_DKM521C30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C31","article-title":"Food and Drug Administration\u2014Center for Drug Evaluation and Research","author":"US","journal-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 3"},{"key":"key\n\t\t\t\t20170511114108_DKM521C32","first-page":"p. 474","article-title":"Differential intrapulmonary disposition of voriconazole and liposomal amphotericin B in noninfected rabbits","author":"Groll"},{"key":"key\n\t\t\t\t20170511114108_DKM521C33","first-page":"p. 410","article-title":"Efficacy of secondary antifungal prophylaxis (SP) and risk factors for breakthrough infection (IFI) after pulmonary IFI in AML patients: a multinational case registry","author":"Cornely"},{"key":"key\n\t\t\t\t20170511114108_DKM521C34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jac\/dkg434","article-title":"Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B","volume":"52","author":"Paterson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511114108_DKM521C35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1099\/jmm.0.05326-0","article-title":"Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients","volume":"53","author":"Dannaoui","year":"2004","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511114108_DKM521C37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170511114108_DKM521C38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/dkh022","article-title":"Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation","volume":"53","author":"Groll","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511114108_DKM521C39","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1248\/bpb.29.2528","article-title":"Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Kawazoe","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"key\n\t\t\t\t20170511114108_DKM521C40","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2005.12.032","article-title":"Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Marty","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20170511114108_DKM521C41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170511114108_DKM521C42","first-page":"124","article-title":"Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation","volume":"1","author":"Ringden","year":"1997","journal-title":"Pediatr Transplant"},{"key":"key\n\t\t\t\t20170511114108_DKM521C43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/61\/3\/734\/16862144\/dkm521.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T05:35:22Z","timestamp":1503466522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkm521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,1,31]]},"published-print":{"date-parts":[[2008,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm521","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}